scholarly journals Small airway function in Finnish COVID-19 survivors

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Anna Lindahl ◽  
Jere Reijula ◽  
Leo Pekka Malmberg ◽  
Miia Aro ◽  
Tuula Vasankari ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Acute Infection ◽  
Small Airway ◽  
Small Airways ◽  
Airway Function ◽  
Function Impairment ◽  
Alveolar Level ◽  
Nitric Oxide Concentration ◽  
Multiple Measurements

AbstractFollow-up studies of COVID-19 patients have found lung function impairment up to six months after initial infection, but small airway function has not previously been studied. Patients (n = 20) hospitalised for a severe SARS-CoV-2 infection underwent spirometry, impulse oscillometry, and multiple measurements of alveolar nitric oxide three to six months after acute infection. None of the patients had small airway obstruction, nor increased nitric oxide concentration in the alveolar level. None of the patients had a reduced FEV1/FVC or significant bronchodilator responses in IOS or spirometry. In conclusion, we found no evidence of inflammation or dysfunction in the small airways.

Relationship between alveolar nitric oxide concentration in exhaled air and small airway function in COPD

2013 ◽  
Vol 7 (4) ◽  
pp. 046002 ◽  
Author(s):  
Tsunahiko Hirano ◽  
Kazuto Matsunaga ◽  
Hisatoshi Sugiura ◽  
Yoshiaki Minakata ◽  
Akira Koarai ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Small Airway ◽  
Airway Function ◽  
Exhaled Air ◽  
Oxide Concentration ◽  
Nitric Oxide Concentration

scholarly journals Bronchodilator Response Predicts Longitudinal Improvement in Small Airway Function in World Trade Center Dust Exposed Community Members

2019 ◽  
Vol 16 (8) ◽  
pp. 1421 ◽  
Author(s):  
Deepak Pradhan ◽  
Ning Xu ◽  
Joan Reibman ◽  
Roberta M. Goldring ◽  
Yongzhao Shao ◽  
...  
Keyword(s):  
World Trade ◽  
World Trade Center ◽  
Small Airway ◽  
Forced Oscillation Technique ◽  
Small Airways ◽  
Bronchodilator Response ◽  
Airway Injury ◽  
Airway Function ◽  
Trade Center ◽  
Over Time

The evolution of lung function, including assessment of small airways, was assessed in individuals enrolled in the World Trade Center Environmental Health Center (WTC-EHC). We hypothesized that a bronchodilator response at initial evaluation shown by spirometry or in small airways, as measured by forced oscillation technique (FOT), would be associated with improvement in large and small airway function over time. Standardized longitudinal assessment included pre and post bronchodilator (BD) spirometry (forced vital capacity, FVC; forced expiratory volume in 1 second, FEV1) and FOT (resistance at 5 Hz, R5; resistance at 5 minus 20 Hz, R5–20). Longitudinal changes were assessed using linear mixed-effects modelling with adjustment for potential confounders (median follow-up 2.86 years; 95% measurements within 4.9 years). Data demonstrated: (1) parallel improvement in airflow and volume measured by spirometry and small airway function (R5 and R5–20) measured by FOT; (2) the magnitude of longitudinal improvement was tightly linked to the initial BD response; and (3) longitudinal values for small airway function on FOT were similar to residual abnormality observed post BD at initial visit. These findings suggest presence of reversible and irreversible components of small airway injury that are identifiable at initial presentation. These results have implications for treatment of isolated small airway abnormalities that can be identified by non-invasive effort independent FOT particularly in symptomatic individuals with normal spirometry indices. This study underscores the need to study small airway function to understand physiologic changes over time following environmental and occupational lung injury.

Study on small airway function in asthmatics with fractional exhaled nitric oxide and impulse oscillometry

2016 ◽  
Vol 12 (2) ◽  
pp. 483-490 ◽  
Author(s):  
Lin Liu ◽  
Wen Liu ◽  
Chunhong Liu ◽  
Dexiang Wang ◽  
Jiping Zhao ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Exhaled Nitric Oxide ◽  
Small Airway ◽  
Impulse Oscillometry ◽  
Fractional Exhaled Nitric Oxide ◽  
Airway Function

scholarly journals Assessing small airway function for early detection of lung function impairment

2020 ◽  
Vol 56 (1) ◽  
pp. 2001946
Author(s):  
S. Hasan Arshad ◽  
Ramesh Kurukulaaratchy ◽  
Hongmei Zhang ◽  
Claire Hodgekiss ◽  
Wilfried Karmaus ◽  
...  
Keyword(s):  
Lung Function ◽  
Early Detection ◽  
Small Airway ◽  
Airway Function ◽  
Function Impairment ◽  
Lung Function Impairment

Validity of fractional exhaled nitric oxide and small airway function indices in diagnosis of cough-variant asthma

2017 ◽  
Vol 55 (7) ◽  
pp. 750-755 ◽  
Author(s):  
Chen Feng-jia ◽  
Huang Xin-yan ◽  
Lin Geng-peng ◽  
Liu Yang-li ◽  
Xie Can-mao
Keyword(s):  
Nitric Oxide ◽  
Exhaled Nitric Oxide ◽  
Small Airway ◽  
Fractional Exhaled Nitric Oxide ◽  
Cough Variant Asthma ◽  
Airway Function

scholarly journals The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment

2021 ◽  
Vol 10 (4) ◽  
pp. 707
Author(s):  
Wei-Chang Huang ◽  
Pin-Kuei Fu ◽  
Ming-Cheng Chan ◽  
Chun-Shih Chin ◽  
Wen-Nan Huang ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Small Airway ◽  
Adult Patients ◽  
Continuous Treatment ◽  
Asthma Control Test ◽  
Airway Function ◽  
Severe Allergic Asthma ◽  
Forced Expiratory Flow

The implications of boosting Omalizumab treatment (OT) in patients with severe allergic asthma (SAA) remain unclear. The study aimed to explore and compare the 12-month effectiveness between continuous, at least 10-month OT (continuation group) and four-month boost of Omalizumab (boost group) in adult patients with SAA. In this retrospective cohort study, clinical data were collected for further analysis. Of all participants (n = 124), a significant reduction in annual exacerbations (baseline = 0.8 ± 1.5, follow-up = 0.5 ± 1.0, p = 0.047 *) and improvement in small airway ventilation as evaluated by forced expiratory flow at 25–75% (baseline = 55.1 ± 11.1%, follow-up = 59.4 ± 8.4%, p < 0.001 *) were found in the continuation group (n = 110). By contrast, the boost group (n = 14) had significantly increased annual exacerbations (baseline = 0.7 ± 1.4, follow-up = 2.9 ± 3.6, p = 0.031 *) and impaired small airway function (baseline = 55.3 ± 12.9, follow-up = 52.1 ± 12.5, p = 0.026 *). Furthermore, the continuation group rather than the boost group had significant decreases in the frequency of oral corticosteroid (OCS) use as controllers (baseline = 32.7%, follow-up = 20.0%, p = 0.047 *; baseline = 50.0%, follow-up = 21.4%, p = 0.237, respectively) and OCS maintenance dose (mg/month) (baseline = 85.9 ± 180.8, follow-up = 45.8 ± 106.6, p = 0.020 *; baseline = 171.4 ± 221.5, follow-up = 50.0 ± 104.3, p = 0.064, respectively), and increases in asthma control test scores (baseline = 16.0 ± 3.0, follow-up = 19.8 ± 4.4, p < 0.001 *; baseline = 14.6 ± 3.8, follow-up = 19.7 ± 4.7, p = 0.050, respectively). Continuous OT would be beneficial for adult patients with SAA, while boost of Omalizumab would worsen their long-term outcomes.

Sign in / Sign up

Export Citation Format

Share Document